ID   LOPRA-1/5
AC   CVCL_M483
SY   LOPRA-1
DR   DSMZ; ACC-778
DR   DSMZCellDive; ACC-778
DR   Wikidata; Q54902888
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3136791;
RX   PubMed=10936422;
CC   Characteristics: Produces IgA2 kappa.
CC   Doubling time: ~5 days (DSMZ=ACC-778).
CC   Caution: On the basis of its characteristics it seems that LOPRA-1 from DSMZ correspond to the clone described as LOPRA-1/5 in the original publication (PubMed=3136791).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ=ACC-778
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 14
ST   D18S51: 12,17
ST   D19S433: 14,17
ST   D21S11: 28,33.2
ST   D2S1338: 20,26
ST   D3S1358: 14,15
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 11,15
ST   FGA: 20,21
ST   Penta D: 9,11
ST   Penta E: 11,12
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M481 ! LOPRA-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 02-05-24; Version: 12
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3136791; DOI=10.1111/j.1365-2141.1988.00321.x-i1;
RA   Lohmeyer J., Hadam M., Santoso S., Forster W., Schulz A., Pralle H.;
RT   "Establishment and characterization of a permanent human IgA2/kappa
RT   myeloma cell line.";
RL   Br. J. Haematol. 69:335-343(1988).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//